OSR Health (OSRHW) Profit After Tax (2022 - 2026)
OSR Health (OSRHW) posted Profit After Tax of -$3.5 million for Q1 2026, down 135.09% sequentially from $9.9 million in Q4 2025, and up 68.27% YoY from -$2.1 million in Q1 2025.
OSR Health (OSRHW) Profit After Tax (2022 - 2026) Analysis & Trends
OSR Health has reported Profit After Tax for 5 years, with the latest figure at -$3.5 million in Q1 2026.
- Quarterly Profit After Tax rose 68.27% year-over-year to -$3.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.4 million (up 86.34% YoY) and the FY2025 annual result came in at -$12958.0, up 99.87% from the prior year.
- Profit After Tax slipped to -$3.5 million in Q1 2026 per OSRHW's latest filing, from $9.9 million in the prior quarter.
- Over five years, Profit After Tax peaked at $9.9 million in Q4 2025 and troughed at -$10.9 million in Q1 2025.
- A 5-year average of -$1.4 million and a median of -$666367.5 in 2022 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2023 and 2024: Profit After Tax jumped 30612.55% in 2023, then slumped 4393.17% in 2024.
- Over 5 years, Profit After Tax stood at -$14252.0 in 2022, then jumped by 9730.83% to $1.4 million in 2023, then tumbled by 195.64% to -$1.3 million in 2024, then soared by 852.8% to $9.9 million in 2025, then slumped by 135.09% to -$3.5 million in 2026.
- According to Business Quant data, Profit After Tax over the past three periods registered -$3.5 million, $9.9 million, and -$3.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.12 Bn | 131.27 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.30 Bn | 77.31 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 62.84 Bn | 57.66 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 55.67 Bn | 50.53 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.43 Bn | 36.33 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.70 Bn | 28.39 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 27.47 Bn | 9.08 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Royalty Pharma | 27.16 Bn | 26.33 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.03 Bn | 25.87 Bn | 358.27 Mn | -16.62 Mn |
| 10 | OSR Health | 1.40 Mn | 20.39 Mn | 86,605.00 | -4.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.47 Mn |
| Dec 31, 2025 | 9.88 Mn |
| Sep 30, 2025 | -3.63 Mn |
| Jun 30, 2025 | -5.23 Mn |
| Mar 31, 2025 | -10.93 Mn |
| Dec 31, 2024 | -1.31 Mn |
| Sep 30, 2024 | -3.36 Mn |
| Jun 30, 2024 | -2.27 Mn |
| Mar 31, 2024 | -3.36 Mn |
| Dec 31, 2023 | 1.37 Mn |
| Sep 30, 2023 | 78,183.00 |
| Jun 30, 2023 | 301,464.00 |
| Mar 31, 2023 | 110,305.00 |
| Dec 31, 2022 | -14,252.00 |
| Sep 30, 2022 | -20,022.00 |
| Jun 30, 2022 | -988.00 |